Poliserositis in a patient with hepatitis C under treatment with new antivirals

Poliserositis in a patient with hepatitis C under treatment with new antivirals

Saved in:

Bibliographic Details
Main Authors:	Marina Lombardero Pin, Cristina Otero Villalustre, Beatriz Nucete Gallego, Elena Mateos Egido, Lourdes García Reina, Leonor Santos Morín, Alicia Díez Del Pino
Format:	Article
Language:	English
Published:	Elsevier 2016-09-01
Series:	Farmacia Hospitalaria
Online Access:	http://www.aulamedica.es/fh/pdf/10475.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sodium thiosulfate for the treatment of acenocumarol-induced calciphylaxis in a patient with preserved kidney function
by: Attenya Álamo Medina, et al.
Published: (2017-05-01)

Cost effectiveness of a protocol using palivizumab in preterm infants
by: Yolanda Hernández-Gago, et al.
Published: (2017-03-01)

Recent Advances in Antiviral Therapy for Chronic Hepatitis C
by: Akihiro Tamori, et al.
Published: (2016-01-01)

Current trends and advances in antiviral therapy for chronic hepatitis B
by: Juan Li, et al.
Published: (2024-12-01)

Antiviral therapy and regression of liver fibrosis at chronic hepatitis B
by: D. T. Abdurakhmanov
Published: (2010-02-01)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
by: Yosra Zaimi, et al.
Published: (2021-10-01)

Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient
by: Giovanni Varotti, et al.
Published: (2021-01-01)

Self-reported experience in patients treated with Hepatitis C direct acting antivirals
by: Irene Cañamares Orbis, et al.
Published: (2016-12-01)

Effect of Health Literacy on Antiviral Treatment of Hepatitis B: Instrumental Variable Analysis
by: Hanchao Cheng, et al.
Published: (2024-12-01)

Predictors of Antiviral Therapy in a Post-Transfusion Cohort of Hepatitis C Patients
by: Maciej Witkos, et al.
Published: (2006-01-01)

Elderly Patients Are at Greater Risk of Cytopenia During Antiviral Therapy for Hepatitis C
by: CG Nudo, et al.
Published: (2006-01-01)

Biochemical Evolution and Histological Response of Patients with Hepatitis C Undergoing Antiviral Therapy.
by: Omar Julián Hernández Ojeda, et al.
Published: (2011-07-01)

Antiviral therapy for chronic hepatitis C: is there a time to change existing standards?
by: D. T. Abdurakhmanov
Published: (2009-02-01)

Intrahepatic Exhausted Antiviral Immunity in an Immunocompetent Mouse Model of Chronic Hepatitis BSummary
by: Satoshi Shigeno, et al.
Published: (2025-01-01)

Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study
by: Guanghui Ren, et al.
Published: (2025-02-01)

Viral Response to Specifically Targeted Antiviral Therapy for Hepatitis C and the Implications for Treatment Success
by: Curtis L Cooper
Published: (2010-01-01)

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
by: Sylvia Drazilova, et al.
Published: (2018-01-01)

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
by: Hee Bok Chae, et al.
Published: (2013-01-01)

Two ways to one goal: new strategy of antiviral therapy for chronic hepatitis C
by: S. N. Batskikh
Published: (2012-11-01)

Sarcoid-like reaction at the patient with chronic hepatitis C on a background of antiviral therapy
by: A. V. Lapshin, et al.
Published: (2010-06-01)

P-82 IMPACT OF HEPATITIS C VIRUS ERADICATION WITH DIRECT ANTIVIRAL DRUGS ON GLYCEMIC CONTROL AFTER LIVER TRANSPLANTATION
by: Alicia Araújo de Oliveira, et al.
Published: (2024-12-01)

Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies
by: Fei Yu, et al.
Published: (2024-12-01)

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Long-term results of antiviral therapy in patients with chronic hepatitis C with sustained virologic response
by: T. M. Ignatova, et al.
Published: (2013-09-01)

Intelligent MONitoring System for antiviral pharmacotherapy in patients with chronic hepatitis C (SiMON-VC)
by: Luis Margusino-Framiñán, et al.
Published: (2017-01-01)

Knowledge and awareness of perinatal antiviral use in the prevention of mother-to-child hepatitis B virus transmission among maternal chronic hepatitis carriers
by: Jia Ming Low, et al.
Published: (2024-09-01)

Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”
by: Beom Kyung Kim
Published: (2024-10-01)

USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS
by: Claudio Ucciferri, et al.
Published: (2010-02-01)

USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS
by: Paola Mancino, et al.
Published: (2010-03-01)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
by: L. Tang, et al.
Published: (2018-01-01)

Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience)
by: I. Yu. Pirogova, et al.
Published: (2018-08-01)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
by: Abbas Abbas, et al.
Published: (2020-12-01)

An ODEs multiscale model with cell proliferation for hepatitis C virus infection treated with direct acting antiviral agents
by: Hesham A. Elkaranshawy, et al.
Published: (2024-12-01)

Direct-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis
by: Hsuan-Yu Hung, et al.
Published: (2024-12-01)

Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review
by: Ioana Adela Ratiu, et al.
Published: (2024-12-01)

Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents
by: Zhang Y, et al.
Published: (2025-01-01)

Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients
by: Jiayi Wang, et al.
Published: (2024-12-01)

Determinants of Antiviral Treatment Initiation in a Hepatitis C-infected Population Benefiting from Universal Health Care Coverage
by: Romain Moirand, et al.
Published: (2007-01-01)

Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil
by: Elodie Bomfim Hyppolito, et al.
Published: (2024-11-01)

Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
by: Seren M. Gedallovich, et al.
Published: (2024-10-01)